Zealand Pharma AS

ZLDPF

Company Profile

  • Business description

    Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

  • Contact

    Sydmarken 11
    SoborgDK-2860
    DNK

    T: +45 88773600

    E: [email protected]

    https://www.zealandpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    578

Zealand Pharma AS News & Analysis

stocks

2 companies poised to capitalize on the rise of GLP-1 drugs

Why Pfizer and Roche look like top choices for investors in the war to tip the scales.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,720.50116.10-1.31%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,097.061,101.11-2.19%
FTSE 10010,452.6898.49-0.93%
HKSE22,841.62453.13-1.95%
NASDAQ23,879.20550.69-2.25%
Nikkei 22558,215.981,228.23-2.07%
NZX 50 Index14,129.92117.33-0.82%
S&P 5007,175.83147.80-2.02%
S&P/ASX 2008,617.30113.10-1.30%
SSE Composite Index3,577.6210.21-0.28%

Market Movers